23andMe

23andMe Launches Month-Long Initiative to Amplify ARRAY’s “Seat16” Program for Acclaimed Film ORIGIN by Ava DuVernay

Retrieved on: 
Wednesday, January 31, 2024
ARRAY, Pulitzer, Knowledge, Human, History, DNA, Origin, Academy Awards, Pulitzer Prize, Beauty, 23andMe

SUNNYVALE, Calif., Jan. 30, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading genetic health and biopharmaceutical company, announced a month-long initiative to amplify Ava DuVernay’s new film ORIGIN and the film’s groundbreaking Seat16 program.

Key Points: 
  • SUNNYVALE, Calif., Jan. 30, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading genetic health and biopharmaceutical company, announced a month-long initiative to amplify Ava DuVernay’s new film ORIGIN and the film’s groundbreaking Seat16 program.
  • For 23 days, 23andMe will donate 100 seats daily to support the program.
  • ARRAY, the multi-platform arts and social impact collective founded by Ava DuVernay, created the Seat16 initiative to ensure that 10,000 young people across the nation get to experience ORIGIN.
  • Through her foundation, 23andMe co-founder and CEO Anne Wojcicki helped fund the film along with several other non-profits.

23andMe Announces FDA Clearance of IND Application for its Dual Mechanism Antibody, 23ME-01473, Targeting ULBP6

Retrieved on: 
Wednesday, January 31, 2024
Immune system, Trial of the century, Genetics, NK, Patient, FDA, Database, Food, FC, Cell death, Therapy, Cancer, 23andMe, NKG2D, Vaccine

23andMe plans to evaluate ‘1473 in participants with advanced solid tumors in a Phase 1 clinical study beginning in the first half of 2024.

Key Points: 
  • 23andMe plans to evaluate ‘1473 in participants with advanced solid tumors in a Phase 1 clinical study beginning in the first half of 2024.
  • ‘1473 targets ULBP6 to restore anti-tumor immunity through NK and T cells.
  • Further, ‘1473 is Fc-effector enhanced, which provides an additional mechanism for NK cells to induce cell death of ULBP6-expressing cancer cells.
  • “This program further validates the 23andMe database as a proven resource for identifying novel therapeutic targets,” said Jennifer Low, Head of Therapeutics Development, 23andMe.

Regula Urges Awareness as Identity Theft Soars to a Record 3205 Data Compromises

Retrieved on: 
Tuesday, January 30, 2024
Transfer, IDV, Ashkenazi Jews, Roger Hawkins (drummer), Record, Identity theft, American Express, Facial recognition, Face, Weapon, NFC, Sheep, Identity, AI, Iris, 23andMe, Theft, Airport, Regula, Apple, Goat, RFID, ID, Annual report, Progress Software, MyGov, Changi Airport, Cryptocurrency

RESTON, Va., Jan. 30, 2024 /PRNewswire/ -- In a landscape saturated with staggering statistics, the need for innovative solutions to safeguard against the usage of stolen identities becomes more pronounced. The gravity of identity-related crimes is illustrated by the Identity Theft Resource Center's annual report, disclosing a record 3205 data compromises in 2023, marking a seismic 78% increase from the prior year. These breaches facilitated hackers in gaining unauthorized access to the personal information of millions of consumers.

Key Points: 
  • Amidst an alarming surge in identity-related crimes, Regula, a global developer of forensic devices and identity verification solutions, calls for heightened vigilance during Identity Theft Awareness Week.
  • The gravity of identity-related crimes is illustrated by the Identity Theft Resource Center's annual report , disclosing a record 3205 data compromises in 2023, marking a seismic 78% increase from the prior year.
  • Shields Healthcare Group, a Massachusetts-based medical services provider, saw the theft of sensitive patient information and confidential data in a breach that affected approximately 2.3 million people.
  • The breach exposed large volumes of often-sensitive data, including pension information, social security numbers, medical records, and billing data.

23andME CANADIAN CONSUMER DATA BREACH CLASS ACTION

Retrieved on: 
Wednesday, December 20, 2023
Class, Supreme court, Representation, 23andMe, Defendant, Prejudice

VANCOUVER, BC and TORONTO, ON, Dec. 20, 2023 /CNW/ - The Supreme Court of British Columbia has granted a Representation Order subject to proposed class proceedings brought in the matter of J. R. v 23andMe Holding Co et al, Vancouver Registry, S-237147.

Key Points: 
  • VANCOUVER, BC and TORONTO, ON, Dec. 20, 2023 /CNW/ - The Supreme Court of British Columbia has granted a Representation Order subject to proposed class proceedings brought in the matter of J. R. v 23andMe Holding Co et al, Vancouver Registry, S-237147.
  • This class action has been brought on behalf of a proposed Class comprising of all Canadian customers of 23andMe who were affected by the data breach reported by the company in October 2023 ("Class"), excluding certain individuals affiliated with the Defendants.
  • 23andMe's Terms of Service dated November 30, 2023 include provisions for alternative dispute resolution and individual arbitration procedures and a class action waiver, and require that customers opt out if they wish to not be bound by those terms.
  • Pursuant to the Representation Order, Representative Plaintiff and Representative Counsel are empowered to address those issues on behalf of putative members of this class action.

23andMe Reports Second Quarter Fiscal 2024 Financial Results

Retrieved on: 
Wednesday, November 8, 2023
FDA, Research, African Americans, 23andMe, PGS, Health, Science, CORE (research service), Society for Immunotherapy of Cancer, Behavior, BRCA1, Consumer, Genetics, EBITDA, Workforce, Health Action International, Premium, Bangladesh Technical Education Board, Inflammation, BRCA2, DNA, Advertising, Pharmacokinetics, Consumer service, SITC, Science (journal), Immunotherapy, Database, Growth, Marketing, Webcast, GSK, GSK plc, Blood, Society, African, Total, Table, Pharmacogenomics, Harvard University, Lijun International Pharmaceutical (Holding) Co. Ltd., SAN, Pharmaceutical industry, Mobile phone, CD200R1, Simvastatin, Therapy

SOUTH SAN FRANCISCO, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and biopharmaceutical company, reported its financial results for the second quarter of fiscal year 2024 (FY24), which ended September 30, 2023.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and biopharmaceutical company, reported its financial results for the second quarter of fiscal year 2024 (FY24), which ended September 30, 2023.
  • Members of Total Health will also receive all the reports and features offered in our existing 23andMe+ Premium Membership.
  • Full year Adjusted EBITDA deficit is reaffirmed to be in the range of $180 to $160 million for fiscal year 2024.
  • 23andMe will host a conference call at 4:30 p.m. Eastern Time today, November 8, 2023, to discuss the financial results for Q2 FY2024 and report on business progress.

23andMe Launches Total Health™, its Comprehensive, Prevention-Based Health Membership

Retrieved on: 
Tuesday, November 7, 2023
Knowledge, FDA, Medical genetics, American College, 23andMe, DPYD, Genetic testing, ACMG, Polygene, Biomarker, Health, Ovarian cancer, Therapy, Life, BRCA1, Reading, Genetics, Citalopram, Liver, Kidney, Research, Prostate cancer, Clinical Pharmacogenetics Implementation Consortium, Pharmacogenomics, Metabolism, Genomic Health, BRCA2, Genome, Heredity, Disease, LDL, CYP2C19, Risk, Asthma, Risk assessment, Cancer, Breast cancer, Saliva, Pancreatic cancer, PGS, Fetus, Gene, SLCO1B1, Anxiety, Breast, American College of Medical Genetics and Genomics, Lijun International Pharmaceutical (Holding) Co. Ltd., Cholesterol, SAN, DNA, Pharmaceutical industry, Medical imaging, Vaccine, Medical device, Dietary supplement

SOUTH SAN FRANCISCO, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading genetic health and biopharmaceutical company, today launched 23andMe+ Total Health, its new, comprehensive prevention-based health membership that provides clinical grade exome sequencing, biannual blood testing, and unprecedented access to genetics-based clinical care.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading genetic health and biopharmaceutical company, today launched 23andMe+ Total Health, its new, comprehensive prevention-based health membership that provides clinical grade exome sequencing, biannual blood testing, and unprecedented access to genetics-based clinical care.
  • Members of Total Health will also receive all the reports and features offered in the Company’s existing 23andMe+ Premium Membership .
  • As part of Total Health, members will gain access to all the premium reports and features delivered through 23andMe+ Premium.
  • The 23andMe+ Total Health membership will cost $99 per month, billed in a one-time annual payment of $1,188.

New to The Street TV Announces the Interviews of Four Corporate Guests, Episode 526, Airing on Bloomberg TV as Sponsoring Program, Tonight, Thursday, November 2, 2023, 9:30 PM PT

Retrieved on: 
Thursday, November 2, 2023
Dark, Sewage, Social media, FRA, Inc., Genetics, FORM, Clean Seas Seafood, Interview, Third party, Economic development, ERM, Hacking, Record, FSE, IP, Birthday, Sale, GPS, Goldman, Internet, United Security Bancshares, Marketing, Street, Safety, Map, Web page, 23andMe, CDI, BEC, Pyrolysis, Coffee, CSE, Growth, Privacy, Communication, Email spoofing, Government, OTCQX, PROMO, Electricity, Akamai Technologies, Pointman, MasterCraft, Online shopping, Engineering

Precision Mapping Solutions – ProStar Holdings, Inc.'s (OTCQX: MAPPF) (TSXV: MAPS) (FSE: 5D00) ($MAPPF) interview with Page Tucker, Chief Executive Officer .

Key Points: 
  • Precision Mapping Solutions – ProStar Holdings, Inc.'s (OTCQX: MAPPF) (TSXV: MAPS) (FSE: 5D00) ($MAPPF) interview with Page Tucker, Chief Executive Officer .
  • From the Nasdaq MarketSite Studio, New to The Street's TV Host Jane King interviews Dan Bates , Chief Executive Officer of Clean Vision Corp .
  • The Company recently filed a FORM S-1 registration statement with the United Securities and Exchange Commission and awaits government approval.
  • The West Virginia Department of Economic Development granted the Company $15 Million in low-interest loans to move forward with the Quincy plant.

23andMe Launches Health Action Plan to Provide Personalized Recommendations Based on Genetic and Other Health Data

Retrieved on: 
Tuesday, October 31, 2023
Stroke, Research, 23andMe, Metabolic syndrome, HI, Product management, OK, Exercise, Learning, RI, Lipid, Risk, Triglyceride, PR, Blood, Sleep, Diet, Lijun International Pharmaceutical (Holding) Co. Ltd., Metabolism, SAN, DNA, Dietary supplement

Eligible customers may also receive recommendations for further clinical action, like getting a blood test, which can now be coordinated directly through 23andMe.

Key Points: 
  • Eligible customers may also receive recommendations for further clinical action, like getting a blood test, which can now be coordinated directly through 23andMe.
  • * The biomarker data, in addition to genetic data, can help identify possible health risks for individuals to take any necessary actions.
  • “Health Action Plan is a powerful tool for customers, combining genetic and non-genetic data, along with lab testing to tailor health recommendations,” said Robin Smith, Ph.D., Director of Product Management at 23andMe.
  • 23andMe reminds customers that they should not use Health Action Plan to replace a visit to their primary healthcare provider.

23andMe Announces Collaboration Extension with a New Data Licensing Agreement with GSK

Retrieved on: 
Monday, October 30, 2023
Artificial intelligence, Whole genome sequencing, Genetics, Database, GSK, 23andMe, Entrepreneurship, FirstBank Holding Co, Research, Machine learning, SAN, GSK plc, Human genetics, Pharmaceutical industry

Under an amendment to their Collaboration Agreement, 23andMe will receive a $20 million upfront payment for a one year, non-exclusive data license.

Key Points: 
  • Under an amendment to their Collaboration Agreement, 23andMe will receive a $20 million upfront payment for a one year, non-exclusive data license.
  • The license will also include access to certain services such as further analyses of the 23andMe data not provided in the core data release.
  • Any new drug discovery programs that GSK chooses to initiate during the agreement will be owned and advanced solely by GSK.
  • 23andMe and GSK both retain royalties on a number of active programs developed under the initial collaboration.